Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
## Adult Dosing
* **Erosive Esophagitis:** 40 mg orally once daily for up to 8 weeks. A second 8-week course may be considered for patients who have not healed.
* **Maintenance of Healing of Erosive Esophagitis:** 40 mg orally once daily. The duration of maintenance therapy should be determined by physician assessment.
* **Pathological Hypersecretory Conditions:** Start with 40 mg orally twice daily. Doses may be adjusted upward based on clinical response. Doses up to 240 mg once daily (divided into two doses) have been given.
**Maximum Daily Oral Dose:** 240 mg.
## Pediatric Dosing
* **Erosive Esophagitis (12 years and older):** 40 mg orally once daily for up to 8 weeks.
* **GERD (5 years and older):** 20 mg to 40 mg orally once daily for up to 8 weeks.
* **GERD (less than 5 years):** Dosing in this age group is not well-established and depends on clinical judgment and local protocols. Commonly used doses range from 10 mg to 20 mg once daily.
## Dose Adjustments
No dose adjustment is generally required for patients with renal impairment or mild to moderate hepatic impairment. For severe hepatic impairment, the recommended dose is 20 mg once daily.
## Contraindications
Known hypersensitivity to pantoprazole or any component of its formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, and flatulence. Long-term use of PPIs may be associated with an increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), vitamin B12 deficiency, and hypomagnesemia.
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** PPIs can decrease absorption of drugs like ketoconazole, itraconazole, and certain HIV protease inhibitors (e.g., atazanavir).
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Caution may be warranted with concomitant use of drugs primarily metabolized by this enzyme (e.g., clopidogrel - although clinical significance is debated; citalopram, escitalopram).
## Monitoring
* Monitor for improvement of GERD symptoms.
* Consider monitoring magnesium levels, especially in patients on long-term therapy or concomitant diuretic use.
* Monitor for signs of *Clostridium difficile* infection.
* Assess bone mineral density in patients at risk for osteoporosis.
## Clinical Pearls
* Administer pantoprazole orally 30 minutes before a meal.
* For patients unable to swallow whole tablets, pantoprazole delayed-release **tablets** can be dispersed in 10 mL of non-carbonated water or apple juice and administered immediately. Alternatively, a pantoprazole delayed-release **delayed-release oral suspension** formulation is available. Do not crush or chew pantoprazole delayed-release tablets.
* IV formulation is available for patients unable to take oral medication.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making therapeutic decisions.*
